As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Lantern Pharma Inc. The largest reported stake is Thomas A. Satterfield, Jr.'s, at 7.6%. 7 filings are on record since February 23, 2026 (Schedule 13G/A, July 23, 2026).
Sell to companies like Lantern Pharma Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Empery Asset Management, LP · Sole voting: 0 · Shared voting: 755,891 · Sole dispositive: 0 · Shared dispositive: 755,891 · SCHEDULE 13G/A, 2026-10-13
- · Holder: Empery Asset Management, LP · Percent: 9.99% · SCHEDULE 13G
- · Reporting person: Thomas A. Satterfield, Jr. · Sole voting: 95,000 · Shared voting: 880,000 · Sole dispositive: 95,000 · Shared dispositive: 880,000 · SCHEDULE 13G/A, 2026-07-23
- · Holder: Bios Equity Partners, LP · Percent: 4.48% · Shares: 266,621 · SCHEDULE 13D/A
- · Holder: Bios Equity Partners, LP · Percent: 7.4% · SCHEDULE 13D/A
Lantern Pharma Inc. has 7 Schedule 13D or 13G filings on record since 2026-02-23. 1 holder's latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Thomas A. Satterfield, Jr. | 7.6% | 975,000 | SCHEDULE 13G/A, 2026-07-23 | 2026-06-30 |
| Empery Asset Management, LP | 4.99% | 755,891 | SCHEDULE 13G/A, 2026-10-13 | 2026-09-30 |
| Bios Equity Partners, LP | 4.48% | 266,621 | SCHEDULE 13D/A, 2026-05-15 | 2026-05-15 |
Holding shares or following this stake? See who's behind Lantern Pharma Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Lantern Pharma Inc. and the records around it.
Lantern Pharma Inc. elsewhere on the record
Companies that share a holder
- Thomas A. Satterfield, Jr. also filed stake reports on 8 other companies: Curis, Inc. (May 2026), enVVeno Medical Corporation (Nov 2025), OS Therapies Incorporated (Aug 2025)
- Empery Asset Management, LP also filed stake reports on 21 other companies: Dyadic International Inc. (Oct 2026), Femasys Inc. (Oct 2026), Clene Inc. (Oct 2026)
Watch Lantern Pharma Inc.
Get an email when Lantern Pharma Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Lantern Pharma Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Lantern Pharma Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lantern Pharma Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Thomas A. Satterfield, Jr. | 95,000 | 880,000 | 95,000 | 880,000 | SCHEDULE 13G/A, 2026-07-23 |
| Empery Asset Management, LP | 0 | 755,891 | 0 | 755,891 | SCHEDULE 13G/A, 2026-10-13 |
| Ryan M. Lane | 0 | 755,891 | 0 | 755,891 | SCHEDULE 13G/A, 2026-10-13 |
| Bios Advisors Gp, LLC | 0 | 571,305 | 0 | 571,305 | SCHEDULE 13D/A, 2026-05-15 |
| Aaron G.L. Fletcher | 0 | 571,305 | 0 | 571,305 | SCHEDULE 13D/A, 2026-05-15 |
| Cavu Management, LP | 0 | 571,305 | 0 | 571,305 | SCHEDULE 13D/A, 2026-05-15 |
| Cavu Advisors, LLC | 0 | 571,305 | 0 | 571,305 | SCHEDULE 13D/A, 2026-05-15 |
| Leslie W. Kreis | 0 | 571,305 | 0 | 571,305 | SCHEDULE 13D/A, 2026-05-15 |
| Bios Equity Partners, LP | 0 | 266,621 | 0 | 266,621 | SCHEDULE 13D/A, 2026-05-15 |
| Bios Equity Partners Ii, LP | 0 | 304,684 | 0 | 304,684 | SCHEDULE 13D/A, 2026-05-15 |
| Bios Capital Management, LP | 0 | 571,305 | 0 | 571,305 | SCHEDULE 13D/A, 2026-05-15 |
| Bios Fund Ii Nt, LP | 0 | 28,324 | 0 | 28,324 | SCHEDULE 13D/A, 2026-05-15 |
| Bios Fund Ii Qp, LP | 0 | 211,566 | 0 | 211,566 | SCHEDULE 13D/A, 2026-05-15 |
| Bios Fund Ii, LP | 0 | 64,794 | 0 | 64,794 | SCHEDULE 13D/A, 2026-05-15 |
| Bp Directors, LP | 0 | 26,093 | 0 | 26,093 | SCHEDULE 13D/A, 2026-05-15 |
| Bios Fund I Qp, LP | 0 | 88,769 | 0 | 88,769 | SCHEDULE 13D/A, 2026-05-15 |
| Bios Fund I, LP | 0 | 151,759 | 0 | 151,759 | SCHEDULE 13D/A, 2026-05-15 |
The latest filing identifies Lantern Pharma Inc. by CUSIP 51654W101 and gives its principal executive office as 1920 McKinney Avenue, 7th Floor, Dallas, TX 75201 (SCHEDULE 13G/A, 2026-10-13).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-02-23 | Bios Equity Partners, LP | 8.58% | SCHEDULE 13D/A |
| 2026-04-03 | Thomas A. Satterfield, Jr. | 5.1% | SCHEDULE 13G |
| 2026-04-16 | Bios Equity Partners, LP | 7.4% | SCHEDULE 13D/A |
| 2026-05-15 | Bios Equity Partners, LP | 4.48% | SCHEDULE 13D/A |
| 2026-07-23 | Thomas A. Satterfield, Jr. | 7.6% | SCHEDULE 13G/A |
| 2026-08-04 | Empery Asset Management, LP | 9.99% | SCHEDULE 13G |
| 2026-10-13 | Empery Asset Management, LP | 4.99% | SCHEDULE 13G/A |
Questions about who owns Lantern Pharma Inc.
Who owns Lantern Pharma Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Lantern Pharma Inc.: Thomas A. Satterfield, Jr. (7.6%, Schedule 13G/A, filed 2026-07-23).
When did Thomas A. Satterfield, Jr. buy into Lantern Pharma Inc.?
The filings give report dates, not purchase dates. The earliest filing from Thomas A. Satterfield, Jr. on this page is the Schedule 13G, filed 2026-04-03, reporting 5.1%; its latest, Schedule 13G/A filed 2026-07-23, reports 7.6%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Lantern Pharma Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 21, 2026 | Form D, private offering | — | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Lantern Pharma Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.